logo-loader
RNS
viewAmryt Pharma PLC

Result of AGM

/**/ link{ color: blue }visited{ color: #954F72 } .u{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.u{}p.bc{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif"; font-weight: bold; line-height: normal; margin-bottom: 0cm}span.ba{color:black}p.bd{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center}p.be{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; text-align: center}p.bf{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal}span.m{font-family:"Calibri","sans-serif";color:black;}span.av{color:black;text-decoration:none}p.bg{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; font-weight: bold} p.bh{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:6.0pt;text-align:justify}table.bi{width:448.25pt;margin-left:-7.1pt;border-collapse:collapse}tr.ao{height:15.0pt}td.ar{width:239.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.0pt}p.bj{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 115%}td.ap{width:187.65pt;padding:0cm 5.4pt 0cm 5.4pt; height:15.0pt}p.bk{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height:115%}p.bl{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;line-height:115%}span.an{font-size:11.0pt;line-height:115%;font-family:"Calibri","sans-serif"}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";} span.al{font-size:5.0pt; line-height:115%}p.bm{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: 115%}p.bn{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic}tr.ag{height:16.35pt}td.ai{width:239.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:16.35pt}td.ah{width:187.65pt;padding:0cm 5.4pt 0cm 5.4pt; height:16.35pt}tr.ad{height:4.05pt}td.af{width:239.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:4.05pt}td.ae{width:187.65pt;padding:0cm 5.4pt 0cm 5.4pt; height:4.05pt}p.bo{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif"; font-weight: bold; line-height: 12.65pt; margin-bottom: 0cm} p.bp{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}span.bq{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.br{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.bs{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}span.bt{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.w{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.bu{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.x{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black}span.aa{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}p.bv{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify} /**/
RNS Number : 1015F
Amryt Pharma PLC
10 July 2019
 

10 July 2019

AIM: AMYT
Euronext Growth: AYP

Amryt Pharma plc

("Amryt" or the "Company")

RESULTS OF AGM

Amryt, the biopharmaceutical company focused on rare and orphan diseases, is pleased to announce that at its Annual General Meeting held earlier today, all resolutions, including that to affect the Capital Reorganisation, were duly passed.

 

The full text of each resolution was included in the notice of the meeting, which was posted to shareholders on 12 June 2019, and is available on the Company's website www.amrytpharma.com.

 

Application has been made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM and to Euronext Dublin for the New Ordinary Shares to be admitted to trading on the Euronext Growth Market ("Admission").  It is expected that such Admission will become effective at 8.00 am on 11 July 2019.

 

Following Admission the Company's issued share capital will consist of 45,802,881 New Ordinary Shares. The total number of voting rights in the Company will therefore be 45,802,881 New Ordinary Shares.

 

The ISIN for the New Ordinary Shares is GB00BKB1MS30.

 

Unless otherwise stated, defined terms in this announcement not otherwise defined shall have the same meaning as is ascribed to them in the announcement released on 12 June 2019.

Enquiries:

 

Amryt Pharma plc

+353 (1) 518 0200

Joe Wiley, CEO

Rory Nealon, CFO/COO


 

Shore Capital

+44 (0) 20 7408 4090

Financial Advisor, NOMAD and Joint Broker

 

Edward Mansfield, Mark Percy, Daniel Bush

 

 

Stifel

+44 (0) 20 7710 7600

Joint Broker

 

Jonathan Senior, Ben Maddison

 

 

 

Davy

 

 

+353 (1) 679 6363

Euronext Growth Advisor and Joint Broker

 

John Frain, Daragh O'Reilly

 

Consilium Strategic Communications

+44 (0) 20 3709 5700

Amber Fennell, Matthew Neal, David Daley

 

 

About Amryt

 

Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases.  

 

Lojuxta® is an approved treatment for adult patients with the rare cholesterol disorder - Homozygous Familial Hypercholesterolaemia ("HoFH"). This disorder impairs the body's ability to remove low density lipoprotein ("LDL") cholesterol ("bad" cholesterol) from the blood, typically leading to abnormally high blood LDL cholesterol levels in the body from before birth - often ten times more than people without HoFH - and subsequent aggressive and premature narrowing and blocking of blood vessels.  Lojuxta® is indicated as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without LDL apheresis in adult patients with HoFH.

 

Amryt is the marketing authorisation holder and has an exclusive licence to sell Lojuxta® (lomitapide) across the European Economic Area, Middle East and North Africa, Switzerland, Turkey, Israel, Russia, the Commonwealth of Independent States and the non-EU Balkan states.

 

Amryt's lead development candidate, AP101, is a potential treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no treatment.  It is currently in Phase 3 clinical trials and recently reported positive unblinded interim efficacy analysis results and is anticipated will be fully enrolled by end of H2 2019. The European and US market opportunity for EB is estimated to be in excess of $1 billion.

 

In March 2018, Amryt in-licenced a pre-clinical gene-therapy platform technology, AP103, which offers a potential treatment for patients with Recessive Dystrophic Epidermolysis Bullosa, a subset of EB, and is also potentially relevant to other genetic disorders. 

 

In May 2019, Amryt announced the planned acquisition of Aegerion Pharmaceuticals. This Transaction will put Amryt on the path to creating a rare and orphan disease company with a diversified offering of multiple commercial and development stage assets and will provide it with scale to support further growth. The Transaction will give Amryt an expanded commercial footprint to market two US and EU approved products, lomitapide (Juxtapid® (US/ROW) / Lojuxta® (EU)) and metreleptin (Myalept® (US) / Myalepta® (EU)). Amryt's leadership team already has a deep knowledge of both these products and since December 2016 has successfully commercialized Lojuxta® across Europe and the Middle East.

 

For more information on Amryt, please visit www.amrytpharma.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGEAEXEFAENEFF

Quick facts: Amryt Pharma PLC

Price: 117

Market: AIM
Market Cap: £178.84 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Orphan drug status for new compound 'great news' says Amryt Pharma PLC's COO

Amryt Pharma PLC (LON:AMYT) has been granted orphan drug status in the US for  a compound called AP102 to treat patients with the excess growth condition acromegaly. Chief operating officer Rory Nealon tells Proactive: ''Our focus is to acquire, develop and commercialise products in the...

on 11/07/2016

RNS

Holdings in Company

2 days, 11 hours ago

Share Buyback

6 days, 1 hour ago

Grant of Options

2 weeks, 1 day ago

Trading Update

2 weeks, 1 day ago

Notice of Trading Update

2 weeks, 2 days ago

Holding(s) in Company

3 weeks, 2 days ago

Holdings in Company

on 10/03/2019